Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN 24 FE vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy,Moderate acne vulgaris (in females ≥15 years who have onset of menarche and desire an oral contraceptive for contraception)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Ethinyl estradiol: ~13 hours (range 7–20); norethindrone: ~8 hours (range 5–14). Half-life supports once-daily dosing; steady state achieved within 5–7 days.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism in liver and gut wall, sulfation and glucuronidation. Norethindrone: primarily hepatic reduction and conjugation; metabolized via CYP3A4 and CYP2C9.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Ethinyl estradiol: 40% renal, 60% fecal; norethindrone: 40% renal, 60% fecal.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Ethinyl estradiol: 98% bound to albumin and SHBG; norethindrone: 93% bound to albumin and SHBG.
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Ethinyl estradiol: 2.3–4.0 L/kg; norethindrone: 3.0–4.5 L/kg. Indicates extensive tissue distribution.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Ethinyl estradiol: ~45% (range 38–48%); norethindrone: ~65% (range 60–70%). First-pass metabolism reduces oral bioavailability.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
No specific dose adjustment recommended; use with caution in patients with renal impairment. No GFR-based guidelines established.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic adenomas, acute hepatitis, or decompensated cirrhosis (Child-Pugh class B or C). No dose adjustment recommended in mild hepatic impairment (Child-Pugh class A) but use with caution.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Safety and efficacy established for use after menarche; dose same as adult: one active tablet daily for 24 days then one placebo tablet daily for 4 days. No weight-based dosing.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for postmenopausal women; no specific dose adjustment recommended, but consider increased risk of thromboembolic events and cardiovascular disease in older women.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from oral contraceptive use. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Thromboembolic disorders (e.g., DVT, PE, stroke, MI),Cigarette smoking (increases cardiovascular risk),Hypertension,Gallbladder disease,Hepatic neoplasia (liver tumors),Carbohydrate/lipid metabolism effects (hyperglycemia, hypertriglyceridemia),Headache (including migraine),Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression,Pregnancy and postpartum use,Lactation (may reduce milk production)
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenomas or carcinomas,Known or suspected hypersensitivity to any component of the product,Heavy smoking (>15 cigarettes/day) and age >35 years
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase estrogen levels, but effect is minimal. Take with food if nausea occurs.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, but there is a small increased risk of cardiovascular defects. Second and third trimester exposure may cause fetal harm, including feminization of male fetuses (mild hypospadias) and potential for other teratogenic effects. Use is not recommended during pregnancy.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Combined hormonal contraceptives like LARIN 24 FE are generally not recommended during breastfeeding due to potential suppression of milk production and excretion of small amounts of hormones into breast milk. The M/P ratio is not well established; estrogens and progestins are present in milk at low concentrations. Use in lactating women should be avoided, especially in early postpartum period. Alternative contraception methods are preferred.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
No dose adjustments are applicable as LARIN 24 FE is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased clearance of steroids) are not relevant due to contraindication. Therapy should be discontinued immediately if pregnancy occurs.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LARIN 24 FE is a combined hormonal contraceptive containing ethinyl estradiol and norethindrone. It uses a 24/4 regimen with 24 active pills and 4 iron-containing placebo pills. The iron (ferrous fumarate) in placebo pills is not contraceptive and serves to reduce iron-deficiency anemia risk. Prescribe for contraception, acne, or menstrual disorders. Monitor for VTE risk, especially in smokers over 35. Consider drug interactions with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which reduce efficacy. Breakthrough bleeding is common in the first 3 cycles.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Active pills are light blue; placebo pills are brown and contain iron.,Use backup contraception for the first 7 days if starting after Day 5 of menstrual cycle.,If you miss two or more active pills, take the last missed pill and use backup contraception for 7 days.,Smoking while on this pill increases risk of serious cardiovascular side effects; do not smoke.,Report signs of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,Iron in placebo pills helps prevent anemia but does not provide contraception.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN 24 FE vs DEMULEN 1/50-21, answered by our medical review team.
LARIN 24 FE is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN 24 FE and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN 24 FE is: One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN 24 FE and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN 24 FE is classified as Category C. LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, bu. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.